{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017418","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.977857+00:00","generated_at":"2026-06-09T00:32:33.827592+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NextCure Q3 2023 net loss $14.3M vs $18.9M YoY; cash $118.2M funds into mid-2025","bullets":["Cash and securities $118.2M at Sep 30 2023, down $41.7M from Dec 31 2022; expects funding into mid-2025.","Net loss $14.3M for Q3 2023 vs $18.9M for Q3 2022; narrowed loss due to lower R&D and G&A costs.","R&D expenses $11.0M (down from $13.5M); G&A $4.6M (down from $5.7M).","Phase 1b updates for NC410 and NC762, and NC525 Phase 1a update expected by year end 2023.","Selected LNCB74 (B7-H4 ADC) from LegoChem collaboration; presented data on NC605 and NC181."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017418","json":"https://secwatch.observer/filing/0001558370-23-017418.json","markdown":"https://secwatch.observer/filing/0001558370-23-017418.md","text":"https://secwatch.observer/filing/0001558370-23-017418.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837023017418/0001558370-23-017418-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837023017418/nxtc-20231102x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:32:33.827592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60ec93c20c775a18602b17029ce769dda272b482","claim":"NextCure, Inc. reported quarter ended September 30, 2023 results: net income Net loss was $14.3 million for the quarter ended September 30, 2023.","evidence_excerpt":"NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661059/000155837023017418/0001558370-23-017418-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $14.3 million for the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}